Literature DB >> 10100521

Successful cochlear implantation in a patient with MELAS syndrome.

E L Rosenthal1, P R Kileny, A Boerst, S A Telian.   

Abstract

OBJECTIVE: To describe methods of assessing cochlear implant candidacy in patients with potentially significant peripheral and central nervous system (CNS) degeneration. STUDY
DESIGN: A patient with a degenerative CNS disease (MELAS syndrome) undergoing evaluation for cochlear implantation is described.
SETTING: This study took place at a tertiary care center. PATIENT: A patient with mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) who had cortical blindness and profound sensorineural hearing loss was evaluated and rehabilitated with cochlear implantation.
INTERVENTIONS: Pure-tone audiogram, behavioral responses to promontory stimulation electrical auditory brainstem response, and electrically evoked middle-latency responses (MLRs) were used to assess eighth nerve, auditory brainstem, and cortical auditory pathways. Cochlear implantation with Cochlear Corporation mini 22 implant was performed.
RESULTS: Repeatable electrically evoked MLRs and behavioral responses to promontory stimulation documented the presence of auditory cortical responses. Successful implantation resulted in open set speech recognition and communication using the auditory/oral mode.
CONCLUSION: This report describes successful implantation in a patient with MELAS syndrome and demonstrates the ability to preoperatively confirm the integrity of brainstem and cortical auditory pathways despite significant CNS degeneration.

Entities:  

Mesh:

Year:  1999        PMID: 10100521

Source DB:  PubMed          Journal:  Am J Otol        ISSN: 0192-9763


  9 in total

1.  Mitochondrial cytopathy presenting with focal segmental glomerulosclerosis, hypoparathyroidism, sensorineural deafness, and progressive neurological disease.

Authors:  R Hameed; F Raafat; P Ramani; G Gray; H P Roper; D V Milford
Journal:  Postgrad Med J       Date:  2001-08       Impact factor: 2.401

2.  Cochlear implantation in patients with MELAS syndrome.

Authors:  P D Karkos; S Anari; I J Johnson
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-10-26       Impact factor: 2.503

Review 3.  Cochlear implantation in common forms of genetic deafness.

Authors:  Richard J Vivero; Kenneth Fan; Simon Angeli; Thomas J Balkany; Xue Z Liu
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2010-07-22       Impact factor: 1.675

4.  Sensorineural hearing loss in patients with chronic progressive external ophthalmoplegia or Kearns-Sayre syndrome.

Authors:  C Kornblum; R Broicher; E Walther; S Herberhold; T Klockgether; C Herberhold; R Schröder
Journal:  J Neurol       Date:  2005-04-15       Impact factor: 4.849

5.  Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes syndrome with hypothyroidism and focal segmental glomerulosclerosis in a paediatric patient.

Authors:  Keith K Lau; Samuel P Yang; Maha N Haddad; Lavjay Butani; Sudesh P Makker
Journal:  Int Urol Nephrol       Date:  2007-02-10       Impact factor: 2.370

6.  New criteria of indication and selection of patients to cochlear implant.

Authors:  André L L Sampaio; Mercêdes F S Araújo; Carlos A C P Oliveira
Journal:  Int J Otolaryngol       Date:  2011-10-13

7.  Cochlear Implantation in Patients with Mitochondrial Gene Mutation: Decline in Speech Perception in Retrospective Long-Term Follow-Up Study.

Authors:  Kai Kanemoto; Akinori Kashio; Erika Ogata; Yusuke Akamatsu; Hajime Koyama; Tsukasa Uranaka; Yujiro Hoshi; Shinichi Iwasaki; Tatsuya Yamasoba
Journal:  Life (Basel)       Date:  2022-03-26

8.  Temporal bone histopathology in MELAS syndrome.

Authors:  Ophir Handzel; Omer J Ungar; Dan J Lee; Joseph B Nadol
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-01-07

9.  Cochlear Implantation in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes Syndrome: Case Presentation.

Authors:  Gemma Crundwell; Peter Kullar; Manohar Bance
Journal:  J Int Adv Otol       Date:  2022-01       Impact factor: 1.316

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.